Trademark: 85390442
Word
CBL
Status
Dead
Status Code
710
Status Date
Friday, December 20, 2019
Serial Number
85390442
Registration Number
4333516
Registration Date
Tuesday, May 14, 2013
Mark Type
4000
Filing Date
Friday, August 5, 2011
Published for Opposition
Tuesday, February 26, 2013
Cancellation Date
Friday, December 20, 2019

Trademark Owner History
Chantilly bioPharma - Original Registrant

Classifications
1 Active chemical ingredients and excipients for use in the manufacture of pharmaceuticals consisting of compounds that facilitate delivery of a wide range of pharmaceuticals for pharmaceutical actives
5 Analgesic and muscle relaxant pharmaceutical preparations; Anti-diabetic pharmaceuticals; Antibacterial pharmaceuticals; Cardiovascular pharmaceuticals; Cellulose esters for pharmaceutical purposes; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of a coating for tablets that facilitate the delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical antitussive-cold preparations; Pharmaceutical preparation for skin care; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations, namely, an analgesic for human consumption taken orally; Pharmaceutical preparations, namely, anticoagulants; Pharmaceutical preparations, namely, antidepressants; Pharmaceutical preparations, namely, appetite suppressants; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of joint disease; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical products for treating respiratory diseases; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceuticals, namely, lipid lowering agents

Trademark Events
Dec 20, 2019
Cancelled Sec. 8 (6-Yr)
May 14, 2018
Courtesy Reminder - Sec. 8 (6-Yr) E-Mailed
May 14, 2013
Registered-Principal Register
Feb 26, 2013
Official Gazette Publication Confirmation E-Mailed
Feb 26, 2013
Published For Opposition
Feb 6, 2013
Notification Of Notice Of Publication E-Mailed
Jan 23, 2013
Law Office Publication Review Completed
Jan 23, 2013
Assigned To Lie
Jan 8, 2013
Approved For Pub - Principal Register
Dec 11, 2012
Teas/Email Correspondence Entered
Dec 11, 2012
Correspondence Received In Law Office
Dec 11, 2012
Teas Response To Office Action Received
Aug 13, 2012
Notification Of Non-Final Action E-Mailed
Aug 13, 2012
Non-Final Action E-Mailed
Aug 13, 2012
Non-Final Action Written
Jul 3, 2012
Assigned To Examiner
Jun 6, 2012
Teas/Email Correspondence Entered
Jun 5, 2012
Correspondence Received In Law Office
Jun 5, 2012
Teas Response To Office Action Received
Dec 12, 2011
Notification Of Non-Final Action E-Mailed
Dec 12, 2011
Non-Final Action E-Mailed
Dec 12, 2011
Non-Final Action Written
Nov 30, 2011
Assigned To Examiner
Aug 11, 2011
Notice Of Pseudo Mark Mailed
Aug 10, 2011
New Application Office Supplied Data Entered In Tram
Aug 9, 2011
New Application Entered In Tram

Trademark Alertz updated from USPTO on 2030-01-24